BACKGROUND: An increase in YKL-40 levels seems to correlate with disease severity and poor prognosis in many diseases, including several neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease (AD). Specifically, YKL-40 protein is increased in mild AD with respect to controls, both in cerebrospinal fluid (CSF) and plasma. OBJECTIVE: We hypothesize that subjects in the preclinical (Pre-AD) and prodromal (Prod-AD) stage of AD could already present an increase in CSF YKL-40 levels with respect to healthy controls and idiopathic REM sleep behavior disorder (iRBD) subjects, included as a control group of a distinct neurological disease. METHODS: We measured CSF YKL-40 levels using a commercial ELISA kit in a cohort of 95 subjects, consisting of controls (n = 43), Pre-AD (n = 18), Prod-AD (n = 22), and iRBD (n = 12) subjects. We explored for possible correlations of YKL-40 levels with demographic characteristics, a wide battery of neuropsychological tests, and the AD CSF biomarkers: amyloid-β42 (Aβ42), total-tau protein (t-tau), and phosphorylated-tau protein (p-tau). RESULTS: We detected statistically significant differences between Prod-AD patients and controls. YKL-40 levels showed a significant correlation with t-tau and p-tau levels in the predementia AD continuum and the Pre-AD group. We also observed significant correlations with the MMSE, FCSRT, and M@T tests within the AD continuum, but not in iRBD subjects. CONCLUSION: Our data suggest that CSF YKL-40 levels, although not useful as a diagnostic marker for Prod-AD, may be a valuable marker to detect early physiopathological changes potentially linked with the neurodegenerative process.
BACKGROUND: An increase in YKL-40 levels seems to correlate with disease severity and poor prognosis in many diseases, including several neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease (AD). Specifically, YKL-40 protein is increased in mild AD with respect to controls, both in cerebrospinal fluid (CSF) and plasma. OBJECTIVE: We hypothesize that subjects in the preclinical (Pre-AD) and prodromal (Prod-AD) stage of AD could already present an increase in CSF YKL-40 levels with respect to healthy controls and idiopathic REM sleep behavior disorder (iRBD) subjects, included as a control group of a distinct neurological disease. METHODS: We measured CSF YKL-40 levels using a commercial ELISA kit in a cohort of 95 subjects, consisting of controls (n = 43), Pre-AD (n = 18), Prod-AD (n = 22), and iRBD (n = 12) subjects. We explored for possible correlations of YKL-40 levels with demographic characteristics, a wide battery of neuropsychological tests, and the AD CSF biomarkers: amyloid-β42 (Aβ42), total-tau protein (t-tau), and phosphorylated-tau protein (p-tau). RESULTS: We detected statistically significant differences between Prod-AD patients and controls. YKL-40 levels showed a significant correlation with t-tau and p-tau levels in the predementia AD continuum and the Pre-AD group. We also observed significant correlations with the MMSE, FCSRT, and M@T tests within the AD continuum, but not in iRBD subjects. CONCLUSION: Our data suggest that CSF YKL-40 levels, although not useful as a diagnostic marker for Prod-AD, may be a valuable marker to detect early physiopathological changes potentially linked with the neurodegenerative process.
Entities:
Keywords:
Alzheimer's disease; YKL-40; amyloid-$\beta_{42}$; cerebrospinal fluid; correlation; neuropsychological tests; preclinical; tau protein
Authors: Andrew P Merluzzi; Cynthia M Carlsson; Sterling C Johnson; Suzanne E Schindler; Sanjay Asthana; Kaj Blennow; Henrik Zetterberg; Barbara B Bendlin Journal: Neurology Date: 2018-06-29 Impact factor: 9.910
Authors: Ione O C Woollacott; Jennifer M Nicholas; Carolin Heller; Martha S Foiani; Katrina M Moore; Lucy L Russell; Ross W Paterson; Ashvini Keshavan; Jonathan M Schott; Jason D Warren; Amanda Heslegrave; Henrik Zetterberg; Jonathan D Rohrer Journal: Dement Geriatr Cogn Disord Date: 2020-04-28 Impact factor: 2.959
Authors: Annie M Racine; Andrew P Merluzzi; Nagesh Adluru; Derek Norton; Rebecca L Koscik; Lindsay R Clark; Sara E Berman; Christopher R Nicholas; Sanjay Asthana; Andrew L Alexander; Kaj Blennow; Henrik Zetterberg; Won Hwa Kim; Vikas Singh; Cynthia M Carlsson; Barbara B Bendlin; Sterling C Johnson Journal: Brain Imaging Behav Date: 2019-02 Impact factor: 3.978
Authors: Kelsey E Melah; Sharon Yuan-Fu Lu; Siobhan M Hoscheidt; Andrew L Alexander; Nagesh Adluru; Daniel J Destiche; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Ozioma C Okonkwo; Carey E Gleason; N Maritza Dowling; Lisa C Bratzke; Howard A Rowley; Mark A Sager; Sanjay Asthana; Sterling C Johnson; Barbara B Bendlin Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Unnur D Teitsdottir; Skarphedinn Halldorsson; Ottar Rolfsson; Sigrun H Lund; Maria K Jonsdottir; Jon Snaedal; Petur H Petersen Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Ceren Emre; Khanh V Do; Bokkyoo Jun; Erik Hjorth; Silvia Gómez Alcalde; Marie-Audrey I Kautzmann; William C Gordon; Per Nilsson; Nicolas G Bazan; Marianne Schultzberg Journal: Acta Neuropathol Commun Date: 2021-06-29 Impact factor: 7.801